Patents by Inventor Anna Säll

Anna Säll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL PEPTIDES
    Publication number: 20260146107
    Abstract: The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).
    Type: Application
    Filed: September 15, 2025
    Publication date: May 28, 2026
    Inventors: PETER ELLMARK, KARIN HAGERBRAND, LAURA VARAS, MATTIAS LEVIN, ANNA SÄLL, LAURA VON SCHANTZ
  • NOVEL POLYPEPTIDES
    Publication number: 20260001961
    Abstract: The present invention relates to polypeptides (in particular, bispecific antibodies) including new mutations that reduce immunogenicity and/or improve purity during manufacture.
    Type: Application
    Filed: November 4, 2022
    Publication date: January 1, 2026
    Inventors: Laura von Schantz, Barnabas NYESIGA, Mattias Levin, Anna SÄLL
  • Peptides
    Patent number: 12448465
    Abstract: The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).
    Type: Grant
    Filed: November 13, 2023
    Date of Patent: October 21, 2025
    Assignee: ALLIGATOR BIOSCIENCE AB
    Inventors: Peter Ellmark, Karin Hagerbrand, Laura Varas, Mattias Levin, Anna Säll, Laura von Schantz
  • Bispecific polypeptides against CD137
    Patent number: 12173082
    Abstract: The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD137, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.
    Type: Grant
    Filed: September 23, 2021
    Date of Patent: December 24, 2024
    Assignee: Alligator Bioscience AB
    Inventors: Eva Dahlén, Peter Ellmark, Christina Furebring, Per Norlén, Anna Säll, Laura von Schantz, Niina Veitonmäki, Laura Varas, Jessica Petersson, Sara Fritzell
  • PEPTIDES
    Publication number: 20240117074
    Abstract: The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).
    Type: Application
    Filed: November 13, 2023
    Publication date: April 11, 2024
    Inventors: PETER ELLMARK, KARIN HAGERBRAND, Laura Varas, Mattias Levin, Anna Säll, Laura von Schantz
  • Peptides
    Patent number: 11873348
    Abstract: The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).
    Type: Grant
    Filed: November 4, 2022
    Date of Patent: January 16, 2024
    Assignee: ALLIGATOR BIOSCIENCE AB
    Inventors: Peter Ellmark, Karin Hagerbrand, Laura Varas, Mattias Levin, Anna Säll, Laura von Schantz
  • NOVEL PEPTIDES
    Publication number: 20230312754
    Abstract: The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).
    Type: Application
    Filed: November 4, 2022
    Publication date: October 5, 2023
    Inventors: Peter Ellmark, Karin Hagerbrand, Laura Varas, Mattias Levin, Anna Säll, Laura von Schantz
  • NOVEL BISPECIFIC POLYPEPTIDES AGAINST CD137
    Publication number: 20220213213
    Abstract: The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD137, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.
    Type: Application
    Filed: September 23, 2021
    Publication date: July 7, 2022
    Inventors: Eva DAHLÉN, Peter ELLMARK, Christina FUREBRING, Per NORLÉN, Anna SÄLL, Laura von SCHANTZ, Niina VEITONMÄKI, Laura VARAS, Jessica PETERSSON, Sara FRITZELL
  • NOVEL BISPECIFIC POLYPEPTIDES AGAINST CD137
    Publication number: 20190169308
    Abstract: The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD137, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.
    Type: Application
    Filed: April 24, 2017
    Publication date: June 6, 2019
    Inventors: Eva Dahlén, Peter Ellmark, Christina Furebring, Per Norlén, Anna Säll, Laura von Schantz, Niina Veitonmäki, Laura Varas, Jessica Petersson, Sara Fritzell